Introduction
At the advent of research into natural products,o rganic chemistry was ac rucial tool to establish the chemical structure of compounds.A sar esult, high-yielding,v ersatile, and specific synthetic methods were developed, which led, with the help of innovative strategies,t ot he production of natural products in quantities that otherwise would be inaccessible from natural sources and finally enabled morethorough biological evaluation. Once organic chemists could harness the power of synthesis,t hey were able to modify natural products with an aim to improve the selectivity, potency, stability,a nd pharmacokinetics.S tructure-activity relationship (SAR) properties were investigated by semisynthesis or fragment exchange of natural products,which led to crucial discoveries.
Aprime example in this regard has been the development of statins for the treatment of cardiovascular disease,still the leading cause of death worldwide.A lthough the first generation compounds introduced into the clinic were either identical or closely related to an atural product (lovastatin), the recognition of the crucial 3,5-dihydroxypentanoate scaffold and optimization by medicinal chemistry led to much more improved derivatives,w hich had ad ramatic impact on medicine and society ( Figure 1) . [1] More stringent criteria of "drug likeness" following Lipinskis "rule of five" and related ADME/pharmacokinetic criteria (ADME = adsorbtion, distribution, metabolism, excretion), along with the introduction of high-throughput screening (HTS), led to ap hasing out of natural products in the lead generation process in drug discovery in the late 1990s.However,inthe past 25 years,this paradigm pendent on combinatorial chemistry for medicinal chemistry research has barely provided sufficient numbers of innovative and effective new drugs in Pharma R&D.I nterestingly,h alf of all the new chemical entities (NCEs) introduced over the last 30 years (540 out of 1073) were based on natural products,which underlines their importance for lead generation. [2] Over the last decade,n atural products have been experiencing ar enaissance in drug discovery;t his is based on an umber of reasons,i na ddition to the statistics regarding NCEs presented above.M any studies have revealed striking differences between natural and synthetic compounds,w ith Natural products have had an immense influence on science and have directly led to the introduction of many drugs.Organic chemistry,and its unique ability to tailor natural products through synthesis,provides an extraordinary approacht ou nlockt he full potential of natural products.I nthis Review,ana pproachbased on natural product derived fragments is presented that can successfully address some of the current challenges in drug discovery.These fragments often display significantly reduced molecular weights,r educed structural complexity,areduced number of synthetic steps,w hile retaining or even improving key biological parameters such as potency or selectivity.Examples from various stages of the drug development process up to the clinic are presented. In addition, this process can be leveraged by recent developments sucha sgenome mining,antibody-drug conjugates,and computational approaches.All these concepts have the potential to identify the next generation of drug candidates inspired by natural products.
From the Contents the former being less hydrophobic,h aving more stereogenic centers,alarger fraction of sp 3 -hybridized carbon atoms,more Oa nd less N, S, and halogen atoms,f ewer rotatable bonds, more fused, bridge,o rs piro rings,a nd more solvated hydrogen bond donors and acceptors. [3] After all, these compounds produced by nature are ar esult of millions of years of evolutionary selection and are,h ence,b iologically prevalidated. All these factors have led to the validation of natural products as prime starting points for drug discovery.
One of the main factors often negatively associated with natural products as lead structures constitutes their limited chemical tractability.T he above-mentioned complex architecture,w hich sometimes requires lengthy synthetic approaches,o ften disfavors selection of natural products for further study in aresearch environment that is heavily under pressure in terms of time and financial constraints.I ti st he goal of this Review to showcase with several examples from early development to the clinic that the structural complexity of natural products can be reduced by the chemical synthesis of smaller fragments ("less is more", "reduce to the maximum"), while retaining (or sometimes improving) desired biological parameters such as potency or selectivity.T his Review is not aimed at being comprehensive, [4] but instead should guide the reader through successful design principles and compounds that are at various stages of the development process,f rom lead structure identification to the clinic.T he ultimate goal is shared or complemented by approaches such as "diverted total synthesis", "chemical or molecular editing", [5] and "function-oriented synthesis" (FOS).
[4a, 6] These approaches all present au nique opportunity of retaining desired effects in minimized, biologically active scaffolds as aconsequence of "fragment likeness" with ahigh degree of three dimensional similarity,y et overcome the limitations of parent natural product structures,s uch as lack of accessibility or viable synthetic approachability.I na ddition, these natural product derived fragments could add to the discovery process in the context of fragment-based drug discovery. [7] 2. Natural Product Derived Fragments in Drug Discovery 2.1. Anticancer Activity 2.1.
From Halichondrin Bt oEribulin
Thepolyether macrolide halichondrin B [8] was reported in 1986 by Hirata and Uemura ( Figure 2 ).
[9] It was isolated from the marine sponge Halichondria okadai Kadota, which had been collected off the coast of Japan in the Western Pacific. Later in 1991, Pettit et al. also isolated halichondrin Bf rom an Axinella sp.s ponge,c ollected in Palau. [10] This marine macrolide showed potent activity against B16 melanoma cells (IC 50 = 0.093 ng mL À1 )a nd powerful in vivo inhibition of tumor growth (T/C) [11] in mice (in up to 375 %o ft he test group) over the control group and increased the mean survival times for groups with murine B16 melanoma, P388 leukemia, and l1210 leukemia.
[9b] Later studies revealed that halichondrin Ba cts as at ubulin-destabilizing agent with as lightly different mechanism of action from other antimitotics,s uch as the vinca alkaloids. [8a, 12] More specifically,i t inhibits tubulin polymerization and microtubule assembly, tubulin-dependent GTP hydrolysis,n ucleotide exchange on tubulin, and acts as an oncompetitive inhibitor of the binding of radiolabeled vinblastine to tubulin. [8a,12] Despite this phenomenal biological activity,t he limited supply (less than 210 À6 wt %y ield) [9b] of the natural product from its marine source and the potential for contamination with other closely related halichondrins or highly toxic metabolites, such as okadaic acid, [12] remained serious obstacles that could only seemingly be circumvented by total synthesis.F urthermore,t he amount of material needed to support preclinical development and subsequent clinical trials was estimated to be approximately 10 g. [8a,13] If found to be successful, 1-5 kg year À1 would be necessary to meet commercial needs.A lthough the initial aquaculture with Lissodendoryx sp.s eemed promising,t he ability of scale-up to satisfy the commercial demands in areliable manner could not be achieved.
[8a, 13] Kishi and co-workers reported the first total synthesis of halichondrin B, along with norhalichondrin B, in 1992.
[8a, 14] Ther oute relied on as eries of robust Nozaki-Hiyama-Kishi (NHK) reactions, which were used to construct five key bonds in the synthesis.
[8a, 14a,d,e, 15] Further improvements were later developed, [16] but the optimized synthetic route contained nearly 120 steps.D espite this,t he completion of this landmark total synthesis convinced the U.S. National Cancer Institute (NCI) to move halichondrin Bi nto preclinical development in March 1992.
[13c] TheE isai Research Institute initiated in vitro and in vivo studies of synthetic halichondrin B, along with several analogues provided by the Kishi research group at Harvard University. [17] Surprisingly,t hey found that the C1-C38 macrolide,o rt he "eastern portion" of the molecule,demonstrated activities within an order of magnitude of the parent compound during an in vivo 3-4 day growth inhibition assay with aD LD1h uman colon cancer cell line (Figure 2 ).
[8a, 18] They found that the macrolactone could be replaced by anonhydrolyzable ester bioisostere to prevent susceptibility toward nonspecific esterases.A ttempts to truncate further while retaining activity were unsuccessful. Fore xample,t he 2,6,9-trioxatricyclo[3.3.2.0]decane was essential for the activity and global conformation of the molecule.
[9b]
Despite the success with total synthesis,the limited supply of halichondrin Bwas acritical issue in the early 1990s,which was eased, in particular, by the discovery of the potencyo f simplified analogue eribulin, or E7389 (Figure 2) . [18a] In addition to the synthetic efforts by the Kishi group, [19] the synthesis of the C14-C35 fragment (13)o fe ribulin (Scheme 2) has been optimized for process development on akilogram scale.This most recent route put forth by Eisai Inc. in 2013 begins with conversion of dihydrofuran (1)into C14-C19 fragment 3,through atin-mediated bromoallylation with 2,3-bromopropene (2;S cheme 1). [20] Fragment C20-C26 (5) was synthesized from 1,2-epoxyhex-5-ene (4)i ns even steps by ah ydrolytic kinetic resolution (HKR) with aJ acobsen catalyst. [21] Aldehyde 5 and fragment 3 were then combined in an asymmetric NHK Ni/Cr coupling with chiral ligand 6a, [22] followed by treatment with silica gel to induce formation of the tetrahydrofuran ring. Elaboration of furan 7 through six steps provided the C14-C26 fragment 8.Synthesis of the C27-35 fragment 12 commenced with transformation of readily available d-glucurono-3,6-lactone (9)into C34-C35 diol 10 in eight steps.R eaction of the tetrahydrofuran ring with allyltrimethylsilane,f ollowed by aH orner-WadsworthEmmons olefination and ahydroxy-directed conjugate reduction afforded sulfone 11.S ix additional steps provided the desired C27-35 fragment 12 in af inal yield of 26 %t hrough an entirely chromatography-free,20-step process. TheC 14-C26 (8)a nd C27-C35 (12)s ubunits were combined in an iterative Nozaki-Hiyama-Kishi reaction and Williamson ether cyclization with ligand 6b (Scheme 1) in d.r. = 20:1 and a65%overall yield. Asubsequent reductive cleavage afforded the C14-C35 fragment 13 (Scheme 2). [23] Sulfone 13 was then combined with the C1-C13 aldehyde 14 from the halichondrin Bs ynthesis,w hich was assembled in 13 steps from l-mannonic-g-lactone.
[16b] AS mI 2 -mediated desulfonylation, ak ey Nozaki-Hiyama-Kishim acrocyclization, followed by oxidation were then performed. [24] Additionally,t he Kishi group reported as pecial system for the formation of the trioxatricyclo[3.3.2.0]decane ring system, which involved aD OWEX 50WX8-400 sulfonic acid resin and CaCO 3 work-up of the TBAF-mediated TBS cleavage reaction, followed by filtration and evaporation. [25] Then, passage of the resulting residue through an ion-exchange resin-based device completed the formation of the ketal [16e] in 90 %o verall yield. [26] In vivo studies revealed that eribulin possesses excellent activities at 0.1-1 mg kg À1 against several chemoresistant human solid tumor xenografts. [18a] Eribulin displayed superior efficacyo ver other antimitotics such as even paclitaxel.
[13c]
These studies also confirmed that this analogue could induce G 2 -M cell-cycle arrest and disrupt mitotic spindles,a nd was consistent with the tubulin-based antimitotic mechanism of the parent halichondrin B. Eisai investigated the safety and effectiveness of eribulin mesylate in asingle phase III clinical trial involving 762 women with metastatic breast cancer, during which the median overall survival of patients receiving eribulin mesylate was 13.1 months,w hereas this rate was 10.6 months for those receiving only asingle agent therapy. [27] TheU .S.F DA approved eribulin mesylate (Halaven) on November 15, 2010 for patients with metastatic breast cancer, who have received at least two prior chemotherapy treatments for late-stage disease,i ncluding anthracycline-and taxane-based therapies.T he European Commission has recently followed suit, issuing their approval on July 3, 2014 under the same conditions as the FDA. [28] With this approval in the European Union member states, eribulin mesylate is now approved in more than 50 countries worldwide,i ncluding Japan, Singapore, and Switzerland. Eisai is currently investigating eribulin mesylate as at reatment for breast cancer with fewer prior treatments,a sw ell as soft-tissue sarcoma and non-small-cell lung cancer.
Overall, the development of eribulin constitutes av ast improvement over the parent compound as it has al arge decrease in complexity,i ncluding a3 5% reduction in molecular weight, which requires half the number of synthetic steps to access,a nd retains the potent antitumor activity,asclearly evident by its use today as acancer treatment agent worldwide.
From Migrastatin to aC ore Analogue
Migrastatin was isolated in 2000 by the Imoto group from ac ultured broth of Streptomyces sp. MK929-43F1 (Figure 3 ).
[29] This 14-membered macrolide with ag lutarimide-terminated side chain inhibited the spontaneous migration of EC17 human esophageal and B16 mouse melanoma cells at ac oncentration of 10-30 mgmL
À1
(IC 50 = 82 mgmL À1 ).
[29c]
However,t he compound demonstrated no appreciable cytotoxicity,i nhibition of protein synthesis,o ra ntibiotic/ antifungal activities.I nafollow-up study,t he ability of migrastatin to inhibit the growth of Ms-1 human small cell lung carcinoma cells under anchorage-independent conditions in adose-dependent manner (1-100 mgmL
)implied its influence on integrin signaling,w hich is also involved in cell migration.
[29c] Ay ear after the absolute configuration was confirmed by X-ray crystallography, [30] the Danishefsky group reported the first synthesis of the macrolide by utilizing aL ewis acid catalyzed diene aldehyde condensation (LACDAC)a nd ring-closing metathesis (RCM). [31] Follow-up SAR investigations by the Danishefsky group revealed that, out of eight analogues screened, the migrastatin [32a] Analysis of other analogues revealed that reduction of the C2 À C3 double bond could be tolerated, while modification of the hydroxy group at C9 or at C13, or at the ketone at C1 could not be tolerated with respect to the potent cell migration suppression activity.
[31c] Eight analogues and migrastatin were also tested for their metabolic stability in mouse plasma and, while the parent compound and compounds containing aglutarimide side chain were inert, the most active compounds including the migrastatin core analogue were hydrolyzed rapidly by esterases.These findings resulted in the macrolactam and macroketone analogues being lead compounds from these studies,with IC 50 values of 255 nmol L À1 and 100 nmol L À1 ,r espectively,a nd with no esterase susceptibility.
[34a] As it was suspected that these analogues influence the angiogenesis process,D anishefsky and co-workers also investigated endothelial cell migration with human umbilical vein endothelial cells (HUVECs). These results mirrored the previous ones,i nt hat the analogues showed more activity than the parent compound, albeit with some erosion of potency, and they found that the macrolactam, macroketone,and the macrolactone analogues did not have any cytotoxic or antiproliferative effects up to 20 mmol L À1 in an in vitro mouse assay.
[32a] This observation confirmed that inhibition of cell proliferation is not acontributor to the effects observed in the chamber assays.Ayear later in 2005, Danishefsky and co-workers reported that several analogues,i ncluding the migrastatin macrolactam analogue,i nhibit mammary tumor metastasis in mice,w hich suggests that these compounds interfere with the invasion step by demonstrating that they block Rac activation, lamellipodia formation, and cell migration. [34] In a2010 report, the Danishefsky group reported an even more simple,new macroether (ME) analogue 23 that retains the cancer cell migration inhibition activity of the analogue family (Scheme 3).
[32b] Thes ynthetic sequence towards ME analogue 23 shared the first nine steps of the original route towards the natural product.
[31a-c] Thes ynthesis began with transformation of tartrate derivative 17 into aldehyde 18 by utilizing ah ighly diastereoselective divinylzinc addition. The key LACDAC reaction of aldehyde 18 with diene 19 was performed under a-chelation control in the presence of the Lewis acid TiCl 4 ,and then cyclization with TFAproceeded in 87 %y ield to afford dihydropyranone 20.S elective 1,2-reduction of the ketone and treatment with CSA promoted aFerrier rearrangement to the corresponding lactol 21,which was then transformed into primary alcohol 22 in three steps.A Williamson etherification reaction and RCM afforded ME analogue 23 in 47 %y ield over the five steps.O verall, this analogue had as ignificant reduction in the complexity of migrastatin, yet retained the activity of the parent compound, and was accessed in 11 fewer synthetic steps.
In cell-migration assays,M Ea nalogue 23 demonstrated migration inhibition against several breast cancer cell lines, including the highly metastatic human LM2, without affecting [b] HUVEC human umbilical vein endothelial cells, [31c] and [c] A549 human lung cancer. [33] Scheme 3. Synthesis of the migrastatin macroether analogue by Danishefsky and co-workers (ME, 23). CSA = camphorsulfonic acid, DCM = dichlormethane, 2,6-Lut. = 2,6-lutidine, pyr = pyridine, TBAI = tetrabutylammonium iodide, TFA = trifluoroacetica cid, TBSOTf = tert-butyldimethylsilyltrifluoromethane sulfonate.
the viability of the cells.
[32b] This analogue also inhibited tumor invasion and metathesis,a nd prolonged the overall survival in NOD/SCID mice injected with human breast cancer MDA-MD-231 cells in the abdominal mammary fat pad (human breast cancer xenograft model). [33] In the course of these studies,t he authors also proposed that 23 interferes with fascin-1-dependent migratory behavior. This interaction was confirmed by Chen et al. in 2010 with the X-ray crystal structure of the macroketone analogue in actin-binding sites of fascin. [35] However,there was some debate over this result, as the X-ray structure of the macroketone analogue contained an E-i nstead of the Z-configured double bond between C4 and C5, and the C6 stereocenter was inverted to the S configuration. [36] In 2011, Danishefsky and co-workers reported that 23 was considered to be the most promising analogue on the basis of its in vitro and in vivo activities,p hysical properties,e ase of preparation, and biological stability (Figure 4) . [33] This publication details the promising in vitro and in vivo migration inhibition activity of ME against metastatic small-cell lung carcinoma (SCLC), and also introduced yet another promising candidate,c arboxymethyl-ME (CME), which was synthesized with an aim to enhance the bioavailability and pharmacostability,a nd achieved ah igher potencyw ith lower toxicity than ME. This CME analogue was also used as evidence against the X-ray crystallography studies of Chen et al.:s ince the carboxylic acid functionality reduced cell membrane permeability,a nd this compound retained its potent metastasis inhibition, the findings implied that the primary target is not an intracellular protein such as Fascin, but aprotein target on the cell surface. In 2013, Majchrzak et al. added to this debate by reporting that the migrastatin core analogue showed antibranching activity and interfered with the mechanisms of filopdia assembly,thereby preventing cross-linking of fascin-1-dependent actin filaments in vitro. [37] Overexpression of fascin1 in cancer cells has been linked with clinically aggressive tumors, poor prognosis,a nd shortened disease-free survival. Further studies on these migrastatin analogues and additional structures are ongoing.
From Anguinomycin C/D to an Anguinomycin Analogue
In 1995, Hayakawa et al. reported the structures of anguinomycins Ca nd D, which were isolated from cultures of Streptomyces sp. ( Figure 5 ). [38] These antitumor antibiotics induced cell death in pRB-inactivated glia cells at picomolar concentrations and, surprisingly,c ell-cycle arrest at only the G1 phase was observed for normal rat glia cells.R etinoblastoma tumor suppressor protein (pRB) is often inactivated during the development of avariety of cancers.
Thea bsolute configuration of anguinomycin Cw as confirmed by the first total synthesis in 2007 by Gademann and co-workers.This route had atotal of 29 steps,with 18 steps in the longest linear sequence,a nd an overall yield of 6.7 %. [39] Biological studies demonstrated that this natural product is ap otent inhibitor of CRM1-dependent protein export from the cell nucleus,a na ctivity shared by ac lose structural relative,l eptomycin B. It is known that leptomycin Bc ovalently modifies chromosomal region maintenance 1( CRM1; exportin 1) at the nucleophillic sulphydryl group of Cys 528 by utilizing its a,b-unsaturated d-lactone,thus preventing export of protein cargoes that rely on this cleft by preventing formation of the ternary CRM1/cargo substrate/Ran complex, or the binary complex CRM1/cargo substrate in the absence of Ran. [40] More recent computational studies of inhibitors,s uch as leptomycin B, to CRM1 revealed that the mechanism of inhibition goes beyond simple Michael addition, and is followed by aC RM1-mediated hydrolysis of the lactone. [41] Mutagenesis revealed that at least one of the residues Arg 543, Lys548, or Cys 579 needs to be present to stabilize the resulting anionic tetrahedral intermediate and lower the energy barrier to drive the reaction. Furthermore, evidence not only supported that hydrolysis must follow conjugate addition, as the corresponding hydroxy acids do not inhibit CRM1, but also that hydrolysis decreases the reversibility of the Michael addition and enables persistent binding of the inhibitors to CRM1. This argument is supported by the fact that reversibility of the conjugate addition should be kinetically controlled and the a-proton of the hydrolyzed (carboxylate) intermediate is much less acidic than the corresponding proton of the lactone. [41] Although dose-limiting toxicity prevented further development of leptomycin Basanantitumor agent, [42] Gademann and co-workers saw the potential of the anguinomycin core and went on to synthesize anguinoymcin Dand analogues for further studies with the aim of investigating if the polyketide side chain mimics the hydrophobic leucine-rich nuclear export signal of the cargo protein and is necessary for activity. [43] Theroute employed was similar to the synthesis of the anguinomycin Cd erivative,a nd began with an asymmetric hetero-Diels-Alder reaction between diene 24 and aldehyde 25 with catalyst 26 according to Jacobsen et al., [44] which afforded pyran 27 in 86 %y ield and with 96 % ee (Scheme 4). Thea cetal was inverted to the more thermodynamically stable compound and ah ydrozirconation of the alkyne with the Schwartz reagent, followed by transmetalation with Zn for aN egishi cross-coupling utilizing [PdCl 2 - (DPEphos)] with dibromoolefin 28 [45] to afford diene 29,b ut with inversion to the undesired isomer.I nversion to the desired Z olefin was accomplished with another Negishi cross-coupling reaction to install the ethyl group in 84 % yield and with good selectivity.S ilyl ether 30 was then converted into boronate 31.Aclassic,E vans syn-aldol strategy was employed to assemble vinyl iodide 33 with the DIOZ (4-isopropyl-5,5-diphenyloxazolidin-2-one) auxiliary 32 developed by Hintermann and Seebach. [46] The1 3step route,which was executed in 24 %overall yield, employed the DIOZ auxiliary three times and two boron-mediated aldol reactions.B oronate 31 and vinyl iodide 33 were combined under Suzuki coupling conditions developed by Marshall et al. [47] With ap articular batch of the Suzuki reaction, there was am inor by-product, which was taken with desired product 34 through the last three steps and purified by column chromatography to afford not only anguinomycin D ( 35) , but also aldehyde analogue 36 and truncated analogue 37, likely ad egradation product of the boronate intermediate from the previous Suzuki coupling.
These compounds were then screened for their ability to inhibit CRM1-dependent protein export by measuring the accumulation of Rio2 protein in the HeLa cell nucleus by indirect immunofluorescence analysis.A nguinomycin Ca nd D( Figure 5 ) both displayed partial inhibition at 5nmol L À1 and full inhibition at 10 nmol L À1 while,s urprisingly, aldehyde analogue 36 showed full inhibition at 50 nmol L À1 and truncated analogue 37 exhibited an unexpected strong inhibition at 25 nmol L À1 .T his study demonstrated that the activity could be retained even when the anguinomycin polyketide chain was replaced by ah ydrophobic moiety or when completely removed, and reinforced the importance of the conjugate acceptor ability of the a,b-unsaturated d-lactone. [41] This concept that the anguinomycin core could be reduced by nearly 60 %inmolecular weight and still retain its activity was supported by molecular modeling studies of the (R)-a,b-unsaturated d-lactone in the NES (nuclear export signals) binding pocket of CRM1
[40c-e] with all-atom energy minimization ( Figure 6 ). [49] Further investigations into this more synthetically accessible,t runcated analogue 37 of anguinomycin could provide more powerful or selective nucleocytoplasmic transport inhibitors for cancer treatment. [50] 2.1.4. From Duocarmycin SA to N-Boc-DSA Duocarmycin SA was isolated from Streptomyces sp.D O113 collected from as oil sample at the Rokkakudo temple in Kyoto,J apan in 1990 by Takahashi and co-workers,a nd given its name because it was more stable and demonstrated more potent Gram-positive antibacterial (minimum inhibition concentrations (MICs): 2.7 nmol L À1 for Staphylococcus aureus and 1.4 nmol L À1 for Bacillus subtilis)a nd cytotoxic activities (against murine lymphocytic leukemia P388 and murine sarcoma 180) than close relative duocarmycin A (Figure 7) . [51] Theduocarmycins act as sequence-selective DNAa lkylating agents with 3'!5' binding directionality,s pecific for AT-rich regions in the minor groove,w here stabilizing van der Waals contacts are maximized. [52] Binding of the agent to DNAi nduces ac onformational change,w hich disrupts the stabilization of the vinylogous amide and activates the cyclopropane ring of the cyclopropapyrroloindole in the left-hand side of the core for the reversible,s tereoelectronically controlled adenine-N3 addition in an S N 2f ashion (shape-dependent catalysis).
[52b]
Theb ound agent spans 3.5 base pairs and complements the topological curvature and pitch of the minor groove,with the Angewandte Chemie Reviews hydrophobic face of the molecule implanted deeply within. [53] SAR studies of another close relative,( + +)-CC-1065, identified the required, but not necessarily optimal, pharmacophore for this family of molecules,thus rendering further studies on the more active and stable duocarmycin SA necessary.
Thefirst total synthesis of duocarmycin SA (46), as well as the synthesis of analogue 44 was reported in 1992 by Boger and Machiya (Scheme 5). [54] Tw os uccessive regioselective alkylations of substituted diimide quinone 39 (synthesized in 5steps and 38 %yield) [55] were performed at C5 with dimethyl malonate (38) , and then at C6 with pyrrolidine enamine of pyruvaldehyde dimethyl acetal 40 [56] to afford aniline 41. Acidic conditions removed the acetal group and promoted indole formation, which was followed by cyclization of the resulting diol to complete the dihydropyrroloindole core 42. Eight additional steps,i ncluding chiral resolution of the bis-(R)-O-acetylmandelate esters,p rovided (+ +)-dihydropyrroloindole 43.T his intermediate could then be directly transformed into (+ +)-N-Boc-DSA analogue 44 in 85 %yield, or to the natural antipode of (+ +)-duocarmycin SA (46)bycoupling with the 5,6,7-trimethoxyindole-2-carboxyclic acid salt 45 (made in 3steps and 74 %y ield from 3,4,5-trimethoxybenzaldehyde) [53] in 53 %yield over the two steps.The unnatural (À)-N-Boc-DSA and (À)-duocarmycin SA enantiomers were also synthesized from (À)-ent-43.
Thenatural (+ +)-enantiomers were found to have 10 times more potent in vitro cytotoxicity than the corresponding unnatural (À)enantiomers,w ith IC 50 values (L1210 mouse lymphocytic leukemia) of 10 pmol L À1 for (+ +)-duocarmycin SA and 6nmol L À1 for (+ +)-N-Boc-DSA.
[54b] N-Boc-DSA was found to be as ubstantially less efficient (ca. 10 4 times) DNAa lkylator, with al ess strict selectivity profile than the parent natural product (SA), and with both enantiomers showing the same site reactivity profile.
[52a] Thel atter property was also unusual, but an atural consequence of the diastereomeric relationship of the adducts. N-Boc-DSA was found to be the most stable of the duocarmycin analogues,as measured by chemical solvolysis,w ith complete stability at pH 7a nd ah alf-life of 177 ha tp H3.
[54b] Gas-phase heats of reaction for the alkylation of N-methyladenine with Nacetylduocarmycin Aand N-acetylduocarmycin SA were calculated by using semiempirical methods (AM1, MNDO). The results reflected the experimental observations that the alkylation of DNAi sr eversible (unlike with (+ +)-CC-1065), as the model calculations with methyladenine gave an ear thermally neutral reaction.
[54b] This underlines the importance of noncovalent interactions in the minor groove (hydrophobic binding/van der Waals contacts), as DNAi sn onetheless effectively alkylated by duocarmycins (binding-driven bonding).
Af undamental parabolic relationship for all the duocarmycins was established between the reactivity of the electrophilic cyclopropaner ing and the cytotoxic activity spanning a1 0 4 -10 6 range,w here an increased solvolytic stability or decreased reactivity correlates to an increased cytotoxic potency.
[54b,57] Highly stable analogues do not efficiently alkylate the DNA, while highly reactive analogues do not reach the biological target. Forproof of concept, Boger and co-workers introduced the rationally designed thiophene analogue N-Boc-MeCTI in 2007, which reflected the optimal point of balanced stability and reactivity in the parabolic relationship, being slightly more stable,b ut 5-6 times less potent than N-Boc-DSA (Figure 7) . [57, 58] In this study,t hey also reported analogue MeCTI-TMI, which has an even higher cytotoxic potencyt han duocarmycin SA (IC 50 = 5pmol L À1 versus 10 pmol L
À1
). Ther etained single-digit nanomolar potency of N-Boc-DSA despite asignificant reduction in structural complexity rendered it an excellent example of capturing biological activity with an atural product fragment. 
From Dynemicin At oaDynemicin Analogue
Thev iolet dynemicin Aw as discovered in 1989 in the fermentation broth of Micromonospora chersina sp.( M956-1), isolated from as oil sample from Gujarat State,I ndia ( Figure 8) .
[59] It demonstrated potent Gram-positive antibacterial activity with low toxicity,e specially against Staphylococcus aureus Smith infection (mouse i.p., PD 50 = 0.13 mg kg À1 ), and potent in vivo antitumor activity against B16 melanoma, Moser human carcinoma, HCT-116 human carcinoma, and normal/vincristine-resistant P388 leukemia (IC 50 = 7-9 nmol L À1 ), even prolonging the life span of mice with P388 leukemia or B16 melanoma. Structurally,i t contains au nique hybrid of an anthraquinone and a1 ,5-diyn-3-ene system embedded within astrained 10-membered ring. Theenediyne unit makes it arelative of the esperamicin/ calicheamicin family.T he mechanism of action involves intercalation of the anthraquinone core of into the minor groove of the DNAh elix, followed by attack of the phenyl diradical resulting from the enediyne core,thereby leading to DNAstrand scission of the sugar-phosphate backbone three base-pairs apart. [60] Thep henyl diradical is proposed to form by two sequential one-electron reductions of the hydroquinone to the hydroquinonediol, epoxide opening (key to activation), nucleophilic attack (i.e. water) on the p-quinone methide intermediate or simple tautomerization, and then Bergman cyclization of the strained (Z)-enediyne to the diaryl radical. Dynemicin Apreferentially cuts the 3' side of purine bases with ap reference for guanines,t hus differing from its esperamicin/calicheamicin relatives,a nd demonstrates ap reference for double-stranded (Bform) and stem regions of single-stranded DNA.
Along with several pioneering synthetic studies, [61] the first total synthesis and absolute configuration of (+ +)-dynemicin Aw as reported by Myers et al. in 1995. [62] In total, this route was completed in 26 steps in 0.3 %yield and employed an exo-selective Diels-Alder reaction as the key step.S everal analogues were also made by using the same approach. In the following years,c opious synthetic and SAR studies of enediyne analogues of the dynemicin core were performed by the groups of Schreiber, [69] and others. [64a,d,70] These studies probed the effects of triggering groups or initiators on the nitrogen atom or aryl ring, which could be activated under basic or photochemical conditions that could be mimicked by intracellular processes.T ethering devices were also investigated to aid target delivery,a sw ere deactivating groups that would modulate enediyne activity,aswell as detection devices that would facilitate mechanistic studies. [64a] One of the most potent dynemicin analogues was the sulfone analogue of Nicolaou et al. with an IC 50 value of 20 fm against Molt-4 T-cell leukemia, as compared to an IC 50 range of 0.1 nmol L À1 -0.1 mmol L À1 for dynemicin A ( Figure 8 ) [64a,b,d,71] However,o ne of the most simplified analogues was accessed by Wender et al. in just 7steps (Scheme 6).
[63a] Ther oute began with the reduction of commercially available quinoline carboxyaldehyde (47) and then stepwise incorporation of the enediyne bridge,f irst by ethynyl Grignard addition to the imine to give alkyne 48,f ollowed by formation of the key epoxide and Sonogashira coupling with enyne 49.O xidation of alcohol 50 to the aldehyde and treatment with cesium fluoride permitted closure of the strained 10-membered ring, thereby producing analogue 51.A sc ompared to the parent compound, this greatly simplified analogue exhibited the same activity profile for cleaving plasmid DNA. 
From Bryostatin 1t oP icolog
Theb ryostatin family consists of 20 complex natural products that were isolated from the marine bryozoan Bulgula neritina,s tarting in the late 1960s. [72] They all share a20-membered macrolide core with three densely substituted tetrahydropyran rings and as ignature exocyclic enoate appended to at least one of these rings.T he actual source of these molecules has been narrowed down to ab acterial symbiont of B. neritina, Endobugula sertula,which uses them to protect its larvae from predators.
[73] Themost well-studied member,bryostatin 1, has adiverse and extremely important range of biological activities stemming from its ability to modulate protein kinase C( PKC;F igure 9). [74] Bryostatin 1 exhibits potent anticancer activity by reversing drug resistance,s timulating the immune system, or restoring apopotic function. [75] It either has been or is currently being evaluated in 37 clinical trials for various types of cancer. [76] It has also been shown to enhance memory and learning in animals, reduce Ab peptide build-up in mice,i nduce synaptic contact formation, and reduce postischemic/hypoxic damage resulting from stroke. [77] As such, it has been evaluated in two clinical trials for Alzheimers disease,w ith another trial currently ongoing.I na ddition, bryostatin 1i s also currently being evaluated for HIV/AIDS treatment in yet another clinical trial. Ar ecent study confirmed its ability to activate latent viral reservoirs and downregulate the CD4 cell surface receptor synthesis/expression necessary for viral entry into uninfected cells. [78] Other potential therapeutic applications include treatments for cardiovascular disease, stroke,pain, or cognitive dysfunction.
Despite the remarkable biological activity of the bryostatins,the clinical supply by good manufacturing practice (GMP) is dwindling because of the natural scarcity (isolation yields of 110 À3 to 110 À8 %), the lack of sustainable success with aquaculture or biosynthesis,a nd the lack of facile or scalable routes to these molecules,notwithstanding the synthetic advances of the last 30 years.C urrently,s even total syntheses of bryostatins 7, 2, 3, 16, 1, and 9h ave been reported by the groups of Masamune, [79] Evans, [80] Yamamura, [81] Tr ost, [82] Keck, [83] Wender, [84] and Krische. [85] Theinitial routes were completed in 79-89 steps,with the most recent route towards bryostatin 7
by Krische and co-workers in 2011 being the most efficient with atotal step count of 36 (longest linear sequence:20steps).
In an effort to avoid stepwise limitations of total synthesis,a nd the dose-limiting toxicities of the parent compound, extensive studies on the synthesis and evaluation of bryostatin analogues (bryologs) have been performed, most comprehensively by the Wender research group since the 1980s.Todate,over 100 analogues have been synthesized and screened for various activities,a nd nearly one-third exhibit single-digit nanomolar or even picomolar potencies for PKC binding.
[6d] These studies were primarily driven by the guiding principle that the bryostatin core structure could be divided into the upper "binding" or "recognition domain" (C1-C14) and lower "spacer domain" (C15-C27) according to its interactions with PKC ( Figure 9) . [86] Studies on bryologs have examined the significance of the Aring, [87] the Bring, [88] the C20 [89] and C7 side chains, [90] as well as de novo structures, [91] among others. [92] [93] This represented one of the most potent and promising simplified bryologs,a sthis was realized in 50 fewer synthetic steps than the syntheses towards the parent structure at that time,a nd surpassed its activity (bryostatin 1,
). Thesynthesis of picolog (61)began with the conversion of diol 52 into aldehyde 53 in four steps so that an asymmetric Keck allylation could set the stereocenter at C23 and an acidcatalyzed cyclization/dehydration could form lactone 54 (Scheme 7).
[93b,c] An additional, straightforward seven steps elaborated the pyran ring,i ncluding installation of the acyl Angewandte Chemie Reviews octanoic acid side chain at C20, to give aldehyde 55.T he enal was installed at C15 through azincmediated addition of (Z)-bromo-2-ethoxyethene, followed by acid-induced elimination and then Sharpless dihydroxylation, cleavage of the pyran ketal, and protection with as ilyl group gave intermediate 56,p recursor to the recognition domain. Thespacer domain 60 was synthesized in 10 steps from 4-benzyloxy-2-butanone (57)a nd methyl 5-chloro-5-oxovalerate (58)byemploying two asymmetric Noyori hydrogenations and ad ienolate addition of ethyl acetoacetate (59) in between. Thetwo domains were combined by utilizing aP yBrop-mediated esterification and ad eprotection/macro-transacetalization step to afford picolog (61)i na63 %y ield over the two steps.
As the original synthetic routes towards the parent bryostatin compounds were limited by aJ ulia olefination/lactonization sequence,t he groups of both Wender and Keck sought an ew approach and developed aP rins macrocyclization [94] as ak ey step in back-to-back reports in 2008 (Figure 9 ). This novel tactic allowed access to more complex bryologs in fewer steps than the parent compounds and with even higher potency than picolog. [95] This same powerful strategy was used by Wender and co-workers in 2012 to access bryologs that demonstrated 1000-fold higher potencyt han prostratin, the leading clinical candidate at the time.
[78b] More recent progress has culminated in the Merle series of bryologs from Keck and co-workers, [96] and the most simplified bryologs to-date from Wender et al.-the salicylate-derived class (Figure 9 ). [97] This bryolog shown can be accessed in only 23 steps and displays nanomolar PKC binding affinities.The evolution of the bryolog structures and their broad therapeutic applications has been advancing now for more than 40 years and continues to provide asource of inspiration for discovery. (Figure 10) . [98] This antimicrobial agent demonstrated excellent activity against drug-susceptible and multidrug-resistant M. tuberculosis (MDR-TB or XDR-TB), without significant toxicity in mice.The caprazamycin family (CPZs) are part of the 6'-N-alkyl-5'-b-O-aminoribosoyl-glycluridine class of antibiotics,a nd include liposidomycins (LPMs), which exhibit excellent antimicrobial activities against Grampositive bacteria. [99] Them ode of action of these liponucleosides is inhibition of peptidoglycan synthesis by 
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Reviews inhibition of phospho-MurNAc-pentapeptide translocase (MraY translocase I). MraY is essential for bacterial cell growth, thus making it at arget of interest for the treatment of tuberculosis (TB), [100] and even vancomycin-and methicillin-resistant Staphylococcus aureus (VRSA, MRSA). [101] Although av ery promising antibacterial treatment, CPZ-B has remained synthetically challenging, especially in regard to attaching the unstable fatty acid side chain. This fact, combined with an onerous HPLC separation and apoor water-solubility profile, has prevented it from becoming at herapeutically viable candidate. [102] Only recently has at otal synthesis been reported for the less-active caprazamycin A [103] by Takemoto and co-workers, [104] while Watanabe and co-workers have reported ap artial synthesis of the western portion of CPZ-B. [105] Thus, the primary focus over the years has been on analogues of CPZ, developed primarily by Ichikawa, Matsuda, and co-workers. [106] During their studies, the potency of the diketopiperazine and acyclic analogues revealed that the diazepanone moiety was not essential, but contributory to antibacterial activity. [106b,107] Replacing the diazepanone and aminoribose units with an oxazolidine moiety restricted the flexibility sufficiently to lead to an increase in potencyo fM IC = 2-16 mgmL À1 against MRSA and VRE (vancomycin-resistent enterococci)s trains (oxazolidine analogue;F igure 10). [107] Them ost recent studies include CPZ analogues such as CPZEN-45 with particularly high potency against MDR-TB strains. [102] As the oxazolidine analogues were revealed to be weak MraY inhibitors (IC 50 = 920-1200 mm), Ichikawa et . [108] However,t he morphological changes observed in S. aureus indicated am ode of action that may be completely different from existing peptidoglycan inhibitors.
Them ost potent oxazolidine analogue 65 can be accessed in just 12 steps,starting with an oxidation, twocarbon elongation, and an aminohydroxylation [109] of uridine 62 to afford amino alcohol 63 (Scheme 8). [107] Protecting group manipulations and installation of the oxaziridine ring by condensation with azidoacetaldehyde,f ollowed by acylationa fforded N-palmitoyloxazolidine 64. [107] Finally,c onversion of the methyl ester into the tert-butyl ester by using an isourea derivative followed by reduction of the azide to the amine afforded oxazolidine analogue 65.T he overall reduction in the complexity of this analogue compared to the parent compound is striking,a ll the while retaining its potent antibiotic activity against multidrug-resistant strains. [110] and later identified together with several related molecules in 2003 [111] by Hamburger and co-workers through bioassay-guided fractionation of am ycelial extract of Paecilomyces militaris (RCEF 0095), which displayed pronounced neuritogenic activity in PC-12 cells (Figure 11 ). Isolated from amycelial extract of arelated fungus,f arinosones Aa nd Bs tructurally resemble the militarinones,r etain similar neurite outgrowth activity,a nd exhibit no appreciable cytotoxicity. [112] An umber of other pyridone alkaloids have been synthesized and evaluated in terms of their biological activity. [111, 113] In 2011, Gademann and co-workers developed au nified approach toward several related pyridone alkaloid natural Angewandte Chemie Reviews products. [114] They found that these natural products,t heir enantiomers,a nd some additional isomers with a Z-configured double bond in the side chain demonstrated neuritogenic activity in as tandardized PC-12 assay,t hereby revealing that neither the length of the side chain nor the absolute configuration were essential to the pharmacophore of this molecule family.I n2 013, the Gademann group followed up with further SAR studies and found truncated analogue 69 to have ac omparable neurite outgrowth capacity as farinosone Aa t2 0 mm. [115] Easily synthesized by utilizing the same general route as for the pyridone natural products,p yridone analogue 69 was accessed in just seven steps from ethyl cyanoacetate (66)a nd 12 %o verall yield by utilizing aSuzuki-Miyaura coupling between the brominated pyridone 67 and pinacol borane 68 (Scheme 9). Then euritogenic effects of pyridone analogue 69 could even be observed down to concentrations of 1 mm.F urther investigations mirrored prior biological studies [116] and revealed that this potent analogue,aswell as militarinone D, influence the MAP kinase pathway,a st he neuritogenic effects could be blocked by coincubation with the ERK1/2 inhibitor PD98059 (at 5 mm). Recently,W aldmann and co-workers reported amilitarinoneinspired collection of pyridones,a nd identified the stress pathway kinase MAP4K4 as the target (Figure 11) . [117] Both examples show that by reducing the number of carbon atoms by nearly ahalf,much more simplified, but still potent natural product fragments could be successfully produced.
Miscellaneous Biological Activity
In addition to those presented within this Review,t here are many other notable examples of biologically active, natural product derived fragments ( Figure 12 ). Myers and Herzon demonstrated that avrainvillamide had the same nanomicromolar antiproliferative activity (IC 50 = 50-100 nmol L
À1
)against several cancer cell lines as its structural dimer,stephacidin B. [118] These investigations,including SAR Scheme 9. Synthesis of pyridone analogue 69 by Gademanna nd co-workers. Pin = Pinacol,S EM = trimethylsilylethoxymethyl. Figure 12 . Structural comparisono fa dditional natural product derived, biologically active fragments and their parent compounds.
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Reviews studies of several analogues,e stablished the absolute stereochemical configuration, found that this reversible dimerization occurs through the 3-alkylidene-3H-indole 1-oxide functional group,a ttributed the activity of stephacidin Bt oa rise from dissociation to avrainvillamide (as hypothesized), and identified the nucleolar phosphoprotein nucleophosmin as ab iological target. Thee legant studies of the well-known antibiotic vancomycin and its aglycon by Crowley and Boger found the simplified structure to have more potent activity against av ancomycin-resistant strain than the parent compound (mgmL À1 versus mg mL À1 activity). [119] These investigations reaffirmed the dimeric binding model [120] and addressed the growing vancomycin-resistance issue.Another example is the truncation of the 14-mer cyclic peptide hormone somatostatin (SRIF 14 )tothe 8-mer, octreotide.
[6c, 121] Now marketed by Novartis as the acetate salt, this drug is 70 times more potent than its parent peptide in vivo,a nd is used in the treatment of acromegaly as well as symptoms associated with metastatic carcinoid tumors or vasoactive intestinal peptide-secreting adenomas.T his example showed that it is possible to mimic the activity of natural hormones with at runcated, synthetic analogue,a nd resulted in ac linically successful drug that improves thousands of lives annually.A nother clinically relevant example is that of rostafuroxin, which is asimplified version of the toxic cardiac glycoside ouabain. [122] This antihypertensive agent is currently in phase IIb clinical trials and has been proven to be especially effective for those with genetic abnormalities of adducin and EO (endogenous ouabain) blood pressure regulation. Gademann and co-workers demonstrated that the known siderophore aachelin Hc ould be truncated to its chromophore and reapplied as an anchor to create antifouling and antimicrobial surface coatings for potential use in biocompatible medical devices. [123] In 1994, Nicolaou et al. designed and synthesized truncated brevetoxin analogue [AFGHIJK],w hich was able to bind to the voltage-gated sodium channel and exhibit the same electrophysiological activities as the parent, "red-tide" ladder polyether toxin with an additional four rings. [119b,124] More recently,O verman and co-workers reported the tBu-MacE analogue to have the same Golgi-modifying properties as the parent spongian diterpene macfarlandin E, but with even less cytotoxicity. [125] Our last example is from the studies by Posner and ONeill on analogues of the sesquiterpene trioxane artemisinin. They have reported many simplified aryl derivatives with comparable in vitro antimalarial activities in the nanomolar range,which also function by the iron-induced triggering mechanism and were furthermore effective in rodent models. [126] 3. Additional Sources of Natural Product Fragment Lead Structures
This Review has focused on the identification of suitable fragments through chemical synthesis.L ooking toward the future,h owever,r ecent advancements in structural biology, computational chemistry,a nd genome mining show the potential to identify suitable natural product fragments that might be further refined by chemical synthesis.
Ad ifferent approach to access novel, natural product fragments based on genome data is fueled by advancements in fields such as molecular biology,b ioinformatics,g enetic mapping,a nd structural biology.W ithin the realm of nature, DNA-encoding fragments of compounds are exchanged between organisms and incorporated in new structures, which can sometimes be found in different kingdoms. [127] Then atural product fragments are exchanged within organisms by horizontal gene or fragment gene transfer.A representative example is found in the pederin, theopederin A, and onnamide Afamily of natural products,which share common fragments. [128] Therevolution in genome mining and advances in metabolomics will continue to unearth even more natural product structures,a tane ver-increasing speed.
Anticancer antibody-drug conjugates (ADCs) are currently the biopharmaceutical standard for innovative cancer treatments,w ith over 30 entities in clinical development. [129] As the name suggests,a na ntibody is linked to ac ytotoxic, natural product derived "payload" to maximize targeting and efficacyo ft he anticancer agent toward the diseased tissue. Lead optimization in this field involves the development of chemical conjugation methods to couple the natural product to the antibody,t he design of the linker,a nd the type of antibody used. [130] Gemtuzumab ozogamicin (Mylotarg) was the first clinically approved ADC.Itwas launched in 2000 in the USA for the treatment of refractory acute myeloid leukemia (AML), specifically for cells bearing the CD33 antigen.
[129a, 131] It contains an N-acetyl-g-calicheamicin dimethyl hydrazide derivative as its active agent, linked by apH-labile hydrazone fragment to arecombinant, humanized IgG4 k antibody,developed by Wyeth and UCB Pharma. This success has led to the evaluation of other cytotoxins for this type of cancer chemotherapy,i ncluding taxanes,a nsamycins, and duocarmycins. [130] More recently,n atural product derived fragments are leading the next generation of ADCs for clinical development.
[129a] There are currently 33 ADCs with natural product derived warheads,ofwhich 10 are in phase II trials and 23 in phase It rials.T hey are derivatives of calicheamicin g1, dolastatin 10 (monomethylaurisatin Ea nd F, MMAE and MMAF), maytansine (DM1 and DM4), doxorubicin, SN-38 (camptothecin, irinotecan derivative), and anthramycin (pyrrolobenzodiazepine,o rP BD,d imer;S GD-1882). It is an exciting time in this relatively new field, as the technologies continue to develop for the efficient production of these natural product derived ADCs.S uccessful lead optimization will likely launch this class of anticancer chemotherapies into predominant clinical use,a nd eventually application toward treatments of other diseases.
Although fragment-based drug design (FBDD) or screening libraries from diversity-oriented synthesis (DOS) seemed to be the contending methods to approach drug development in recent years,i nt he past 2-3 years we have seen an ovel tactic that combines these two methods and involves computational analysis and data mining to create or repurpose natural product derived fragments (NPDFs). [132] This allows for an elegant and systematic identification of biological targets for "orphan" natural products and/or NPDFs,w hich can then be validated through chemical synthesis and subsequent biological assessment. In the pioneering report by Waldmann and co-workers in 2013, they disclosed an innovative algorithm in which 2000 clusters of natural NPDFs were generated from 180 000 natural products,r ich in sp 3 -hybridized centers. [133] Theo verall concept was to identify unexplored ligand classes and areas of chemical space for established drug targets,e specially those that have been difficult to address.T his approach combined the advantages of the chemical space offered by fragments with the rich chemistry and geometry that natural products bring, meanwhile leaving ap ossibility for optimization for biological recognition and modulation. [132] As ap roof-of-concept, they screened and identified novel scaffolds as inhibitors of p38a MAP kinase and tyrosine/dual-specificity phosphatases by using protein X-ray crystallography.T he term "biologyoriented synthesis" (BIOS) has been coined by Waldmann and co-workers for this method. [134] In another example from 2014, Schneider and co-workers developed al igand-based model to predict biological targets for NPDFs that does not require at hree-dimensional target model, but instead relies on the hypothetical polypharmacological character of natural products. [135] To validate their method, they analyzed the antitumor agent archazolid A, and identified eight new biochemical targets for this molecule,all of which have been associated with antitumor effects.A dditional work from the Schneider group has focused on repurposing of de novo created compounds from computational models to predict bioactivity, [136] or on chemography by creating ag enerative topographic map (GTM) to visualize chemical space populated by natural products and synthetic drugs. [137] In 2015, Quinn and co-workers demonstrated that their self-generated NPDF library captured more than half of the small pharmacophore triplet diversity than other natural product datasets, [138] and Lanz and Riedl used NPDFs as seeds for the de novo discovery of lead structures for therapeutically relevant targets. [139] Overall, these examples delineate afuture for this field by proving that the combination of bioinformatic/cheminformatic tools with organic synthesis will enable scientists to expand the boundaries of biologically relevant chemical space.
Summary and Outlook
In this Review,w ea imed to highlight how ad esired property of anatural product, such as its powerful biological activity,c an be retained by as maller, truncated compound ("reduce to the max")-a refined fragment of the parent natural product. This approach addresses some of the shortcomings of the use of natural products in drug discovery.The chemical tractability can be greatly improved by structurally more simple analogues,w ith fewer stereogenic centers and often an overall drastically shorter synthetic route.I nf act, some of the resulting fragments resemble classical medicinal chemistry targets with regard to size and complexity.I n addition, although considerable advances have been made in synthetic methods over the last decades,c hemical synthesis alone cannot likely keep up with the de novo creation of interesting natural product like scaffolds.A sar esult, an umber of potential avenues have opened up the future of this field, including the use of natural product derived fragments in antibody-drug conjugates,s tereochemically complex modules for fragment-based drug discovery,o r scaffold repurposing,a st he next generation of natural product-inspired therapies.
These,a mong other advancements in such fields as structural biology,g enetic mapping,p rotein crystallography, computational chemistry,n anotechnology,a nd genome mining show how natural product fragments can be used to address some of the foreseeable challenges of innovative drug development. All these combined approaches clearly present apromising future role for natural products in drug development. Innovation in these trajectories is key to the future of natural product diversity having an impact on and expanding the breadth of the drug discovery field.
